Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. on May 23, 2013. The filing addresses a corporate governance event involving the departure of a director. Note: The request metadata references "AIM Immunotech Inc.," but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Director Resignation: Richard C. Piani resigned as a member of the Board of Directors and of Hemispherx Biopharma Europe N.V./S.A., effective immediately on May 23, 2013.
- Reason for Departure: Mr. Piani cited health reasons. The Board confirmed the resignation did not result from any disagreement with the Company.
- Committee Roles: Mr. Piani ceased serving as Chairman of the Audit Committee and as a member of the Compensation Committee and Corporate Governance and Nomination Committee.
- Consulting Engagement: The Company engaged Mr. Piani as a consultant to access his expertise. The agreement is month-to-month, terminable with 30 days' notice, at a rate of $3,000 per month.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, or specific risk factors beyond the immediate impact of the director's departure. Management expressed appreciation for Mr. Piani's service since 1995 and his role as Lead Independent Director since 2005.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and the appointment of any replacement for Richard C. Piani.
- Confirm the status of the Audit Committee, as the Chairman has resigned.
- Review subsequent filings to determine if the consulting arrangement with Mr. Piani continues or has been terminated.
- Check for any related disclosures regarding the health status of the former director if it impacts ongoing operations.